French pharma major Sanofi (Euronext: SAN) has launched its insulin glargine and lixisenatide combination drug in the USA under the name Soliqua.
Soliqua 100/33 (insulin glargine and lixisenatide injection), which is known as Suliqua in Europe, is now available by prescription in US pharmacies for the treatment of adults with type 2 diabetes inadequately controlled on basal insulin (less than 60 units daily) or lixisenatide.
"We believe we are providing value to patients and the health care system"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze